Analysis: Cancer drugs top biopharmaceutical deals in 2011

06/3/2012 |

Cancer drugs accounted for nearly 24% of 714 licensing deals and joint ventures in the biopharmaceutical industry last year, according to a Deloitte analysis. Based on disclosed transactions, cancer deals could have been worth $10 billion last year. Despite having fewer deals, the highest median deal size was found in the autoimmune and inflammatory category at $400 million, followed by the endocrine and metabolic area at $163 million.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT